Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells

Emergence of resistance to Tyrosine-Kinase Inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, in Chronic Myelogenous Leukemia (CML) demands new therapeutic strategies. We and others have previously established bortezomib, a selective proteasome inhibitor, as an important potential treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Bucur, Octavian, Stancu, Andreea Lucia, Goganau, Ioana, Petrescu, Stefana Maria, Pennarun, Bodvael, Bertomeu, Thierry, Dewar, Rajan, Khosravi-Far, Roya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796452/
https://www.ncbi.nlm.nih.gov/pubmed/24155950
http://dx.doi.org/10.1371/journal.pone.0077390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796452/
https://www.ncbi.nlm.nih.gov/pubmed/24155950
http://dx.doi.org/10.1371/journal.pone.0077390

Ejemplares similares